Advisory Committee Conflict Of Interest Policy Simplified In Draft Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA presents a consolidated, step-by-step policy to determine eligibility of possible advisory committee participants.
You may also be interested in...
Arcoxia Advisory Committee Will Be Missing Key Participants From 2005 COX-2 Meeting
Many of the key panelists during the 2005 advisory committee review of COX-2 inhibitor cardiovascular safety will not be participating in the Arthritis Advisory Committee's April 12 review of Merck's Vioxx follow-on Arcoxia
Arcoxia Advisory Committee Will Be Missing Key Participants From 2005 COX-2 Meeting
Many of the key panelists during the 2005 advisory committee review of COX-2 inhibitor cardiovascular safety will not be participating in the Arthritis Advisory Committee's April 12 review of Merck's Vioxx follow-on Arcoxia
FDA Must Maintain Conflict of Interest Waivers, Gottlieb Argues
The inability to issue conflict of interest waivers would diminish advisory panels’ importance to the agency, the Deputy Commissioner for Medical & Scientific Affairs said at an event on government panels.